Neurology 2007 Apr 03
Intravenous immunoglobulin therapy for Miller Fisher syndrome.
ABSTRACT
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
Related Questions
The patient returned with recurrent subjective sensory or motor deficits. The initial GQ1B was >1:6400. Two years later, GQ1B was 1:3200.
New answer by at Cedars-Sinai Medical Center (December 5, 2023)
The treatment of MFS is controversial and not addressed in the recently published guidelines. Should a patient exhibit muscle weakness beyond facial and EOM, it could imply an...